IPSEN (OTCMKTS:IPSEY) Shares Gap Up – Still a Buy?

IPSEN (OTCMKTS:IPSEY)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $45.03, but opened at $47.5650. IPSEN shares last traded at $47.5650, with a volume of 142 shares changing hands.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on IPSEY shares. Jefferies Financial Group cut IPSEN from a “hold” rating to a “moderate sell” rating in a research note on Sunday, August 2nd. Zacks Research raised shares of IPSEN to a “hold” rating in a research note on Friday, May 29th. HC Wainwright reissued a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold”.

IPSEN Price Performance

The stock’s 50 day moving average is $45.88 and its two-hundred day moving average is $46.13.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).